专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012054915A3 HOMOZYGOUS AND HETEROZYGOUS IDH1 GENE-DEFECTIVE HUMAN ASTROCYTOMA CELL LINES 审中-公开
标题翻译：异基因和异源IDH1基因缺陷人类ASTROCYTOMA细胞系
公开(公告)号：WO2012054915A3
公开(公告)日：2012-07-19
申请号：PCT/US2011057466
申请日：2011-10-24
申请人： UNIV DUKE , YAN HAI , BIGNER DARELL , GENGLIN JIN
发明人： YAN HAI , BIGNER DARELL , GENGLIN JIN
IPC分类号： C12N5/071 , C12N5/10 , C12Q1/02
CPC分类号： C12N5/0693
摘要： We provide IDH1 gene-defective cell lines (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) derived from dissociated human astrocytoma samples. The cells can be used alone or in combination with each other or other cell types as a tool for determining the impact of IDH1R132H on cellular biology, tumorigenesis, and metabolic profiles. The cell lines may be used to test and identify therapeutic targets and to screen for molecular therapeutic agents.
摘要翻译：我们提供衍生自解离的人类星形细胞瘤样品的IDH1基因缺陷型细胞系（例如，IDH1R132H杂合型和IDH1R132H纯合子）。细胞可以单独使用，也可以彼此组合使用，也可以作为确定IDH1R132H对细胞生物学，肿瘤发生和代谢特征影响的工具。细胞系可用于测试和鉴定治疗靶标并筛选分子治疗剂。

2. 发明申请

WO2012054915A2 HOMOZYGOUS AND HETEROZYGOUS IDH1 GENE-DEFECTIVE HUMAN ASTROCYTOMA CELL LINES 审中-公开
标题翻译：同种异型和杂合型IDH1基因缺陷人星形细胞瘤细胞系
公开(公告)号：WO2012054915A2
公开(公告)日：2012-04-26
申请号：PCT/US2011/057466
申请日：2011-10-24
申请人： DUKE UNIVERSITY , YAN, Hai , BIGNER, Darrell , GENGLIN, Jin
发明人： YAN, Hai , BIGNER, Darrell , GENGLIN, Jin
IPC分类号： C12N5/071 , C12N5/10 , C12Q1/02
CPC分类号： C12N5/0693
摘要： We provide IDH1 gene-defective cell lines (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) derived from dissociated human astrocytoma samples. The cells can be used alone or in combination with each other or other cell types as a tool for determining the impact of IDH1R132H on cellular biology, tumorigenesis, and metabolic profiles. The cell lines may be used to test and identify therapeutic targets and to screen for molecular therapeutic agents.
摘要翻译：我们提供来自解离的人星形细胞瘤样品的IDH1基因缺陷细胞系（例如，IDH1R132H杂合子和IDH1R132H纯合子）。这些细胞可以单独使用或与其他细胞类型组合使用，作为确定IDH1R132H对细胞生物学，肿瘤发生和代谢特征影响的工具。细胞系可用于测试和鉴定治疗靶点并筛选分子治疗药物。

3. 发明申请

US20120202883A1 EFFECTS OF IDH1 AND IDH2 MUTATIONS ON THE CELLULAR METABOLOME 审中-公开
标题翻译： IDH1和IDH2突变对细胞代谢物的影响
公开(公告)号：US20120202883A1
公开(公告)日：2012-08-09
申请号：US13355129
申请日：2012-01-20
申请人： Yan Hai , Darell Bigner , Yiping He , Genglin Jin , Zachary Reitman
发明人： Yan Hai , Darell Bigner , Yiping He , Genglin Jin , Zachary Reitman
IPC分类号： A61K31/191 , A61K31/197 , A61P35/02 , C12Q1/68 , A61P35/00
CPC分类号： A61K31/194 , A61K31/198 , A61K38/05 , G01N33/6812 , G01N2570/00
摘要： Point mutations of the NADP+-dependent isocitrate dehydrogenases (IDH1 and IDH2) occur early in the pathogenesis of gliomas. When mutated, IDH1 and IDH2 gain the ability to produce the metabolite (R)-2-hydroxyglutarate (2HG), but the downstream effects of mutant IDH1 and IDH2 proteins or of 2HG on cellular metabolism are unknown. Here, we profiled >200 metabolites in human oligodendroglioma cell line (HOG) cells to determine the effects of expression of IDH1 and IDH2 mutants. Levels of amino acids, glutathione metabolites, choline derivatives, and tricarboxylic acid (TCA) cycle intermediates were altered in both mutant IDH1- and IDH2-expressing cells. These changes were similar to those identified after treatment of the cells with 2HG. Remarkably, N-acetyl-aspartyl-glutamate (NAAG), a common dipeptide in brain, was 50-fold reduced in cells expressing IDH1 mutants and 8.3-fold reduced in cells expressing IDH2 mutants. NAAG was also significantly lower in human glioma tissues containing IDH mutations than in gliomas without such mutations.
摘要翻译： NADP +依赖性异柠檬酸脱氢酶（IDH1和IDH2）的点突变发生在胶质瘤发病早期。当突变时，IDH1和IDH2获得产生代谢物（R）-2-羟基戊二酸（2HG）的能力，但突变体IDH1和IDH2蛋白质或2HG对细胞代谢的下游作用是未知的。在这里，我们在人类少突神经胶质瘤细胞系（HOG）细胞中分析了200种代谢物，以确定IDH1和IDH2突变体的表达效应。氨基酸，谷胱甘肽代谢物，胆碱衍生物和三羧酸（TCA）循环中间体的水平在突变体IDH1和IDH2表达细胞中都被改变。这些变化与用2HG处理细胞后鉴定的变化相似。值得注意的是，脑中常见的二肽N-乙酰天冬氨酰谷氨酸（NAAG）在表达IDH1突变体的细胞中减少了50倍，表达IDH2突变体的细胞减少了8.3倍。 NAAG在含有IDH突变的人胶质瘤组织中也明显低于没有这种突变的胶质瘤。

4. 发明授权

US09695400B2 Homozygous and heterozygous IDH1 gene-defective human astrocytoma cell lines 有权
公开(公告)号：US09695400B2
公开(公告)日：2017-07-04
申请号：US13878596
申请日：2011-10-24
申请人： Hai Yan , Darell Bigner , Genglin Jin
发明人： Hai Yan , Darell Bigner , Genglin Jin
IPC分类号： C12N5/00 , C12N5/09
CPC分类号： C12N5/0693
摘要： We provide IDH1 gene-defective cell lines (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) derived from dissociated human astrocytoma samples. The cells can be used alone or in combination with each other or other cell types as a tool for determining the impact of IDH1R132H on cellular biology, tumorigenesis, and metabolic profiles. The cell lines may be used to test and identify therapeutic targets and to screen for molecular therapeutic agents.

5. 发明申请

US20130252330A1 HOMOZYGOUS AND HETEROZYGOUS IDH1 GENE-DEFECTIVE HUMAN ASTROCYTOMA CELL LINES 有权
标题翻译：异基因和异源IDH1基因缺陷人类ASTROCYTOMA细胞系
公开(公告)号：US20130252330A1
公开(公告)日：2013-09-26
申请号：US13878596
申请日：2011-10-24
申请人： Hai Yan , Darell Bigner , Genglin Jin
发明人： Hai Yan , Darell Bigner , Genglin Jin
IPC分类号： C12N5/09
CPC分类号： C12N5/0693
摘要： We provide IDH1 gene-defective cell lines (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) derived from dissociated human astrocytoma samples. The cells can be used alone or in combination with each other or other cell types as a tool for determining the impact of IDH1R132H on cellular biology, tumorigenesis, and metabolic profiles. The cell lines may be used to test and identify therapeutic targets and to screen for molecular therapeutic agents.
摘要翻译：我们提供衍生自解离的人类星形细胞瘤样品的IDH1基因缺陷型细胞系（例如IDH1R132H杂合型和IDH1R132H纯合子）。细胞可以单独使用，也可以彼此组合使用，也可以作为确定IDH1R132H对细胞生物学，肿瘤发生和代谢特征影响的工具。细胞系可用于测试和鉴定治疗靶标并筛选分子治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式